Inclusion Criteria:

          -  Written informed consent obtained from the patient/legal representative prior to
             performing any protocol-related procedures, including screening evaluation

          -  Newly diagnosed, untreated, biopsy-proven HPV+ squamous cell carcinoma of the
             oropharynx. Cytologic diagnosis from a cervical lymph node is sufficient in the
             presence of clinical evidence of a primary tumor in the oropharynx. Clinical evidence
             should be documented, may consist of palpation, imaging, or endoscopic evaluation and
             should be sufficient to estimate the size of the primary (for T stage). HPV-positivity
             will be defined as tumors that are p16-positive by immunohistochemistry

          -  Selective stage III-IV disease (T3-T4 or N2-N3 disease) by American Joint Committee on
             Cancer (AJCC) 8th edition as determined by a computed tomography (CT) scan or magnetic
             resonance imaging (MRI) of the head and neck, CT neck, chest, abdomen, pelvis or a PET
             =< 6 weeks of registration

          -  Confirmation of KRAS-variant status as assessed by genotyping from a cheek swab sample
             at MiraDx

          -  Lifetime cumulative smoking history of < 10 pack-years. The cumulative total of the
             number of pack-years during each period of active smoking is the lifetime cumulative
             history

               -  Note: Investigators are discouraged from enrolling patients with a history of
                  very sustained use (such as several years or more) of non-cigarette tobacco
                  products alone given that the effect of non-cigarette tobacco products on the
                  survival of patients with p16-positive oropharyngeal cancers is undefined

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 ? 1 within 60 days
             prior to registration

          -  Hemoglobin >= 9 g/dL (5.58 mmol/L) (within 2 weeks prior to registration)

          -  Absolute neutrophil count (ANC) >= 1500/uL (cells/mm^3) (within 2 weeks prior to
             registration)

          -  Platelet count >= 100,000/uL (cells/mm^3) (within 2 weeks prior to registration)

          -  Total bilirubin =< 1.5 mg/dL (25.65 umol/L) or =< 3.0 mg/dL if the patient has a
             history of Gilbert?s disease (within 2 weeks prior to registration)

          -  Aspartate transaminase (AST)/alanine transaminase (ALT) =< 2 x the institutional upper
             limit of normal (ULN) (within 2 weeks prior to registration)

          -  Serum creatinine =< 1.5 x institutional ULN OR creatinine clearance (measured via
             24-hour urine collection) >= 50 ml/min (that is, if serum creatinine is > 1.5 times
             the ULN, a 24-hour urine collection to calculate creatinine clearance must be
             performed) (within 2 weeks prior to registration)

          -  Female subjects must either be of non-reproductive potential (i.e., post-menopausal by
             history: >= 60 years old and no menses for at least 1 year without an alternative
             medical cause, OR history of hysterectomy, OR history of bilateral tubal ligation, OR
             history of bilateral oophorectomy) or must have a negative serum pregnancy test within
             7 days prior to enrollment

          -  Female subjects of child bearing potential and male subjects with partners of child
             bearing potential must agree to adequate contraceptive measures (hormonal or barrier
             methods) during treatment and for 2 months after the last dose of cetuximab

          -  Subject is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment, scheduled visits, and examinations including follow up

        Exclusion Criteria:

          -  Patients with biopsy-proven metastatic, HPV-negative, KRAS-variant negative, or
             recurrent head and neck squamous cell carcinoma (HNSCC)

          -  Patients with primary site of tumor outside of the oropharynx, specifically of the
             oral cavity, salivary glands, nasal cavity, paranasal sinuses, larynx, hypopharynx, or
             nasopharynx

          -  Patients with prior radiation therapy (RT) that would result in overlap of radiation
             therapy treatment fields (superficial x-ray of skin lesions excluded)

          -  Gross total excision (ex. tonsillectomy) of the primary tumor; however, partial
             removal of the tumor to alleviate an impending airway obstruction does not make the
             patient ineligible. Initial surgical treatment, excluding diagnostic biopsy of the
             primary site or nodal sampling of neck disease, as well as radical or modified neck
             dissection is not permitted

          -  Prior systemic chemotherapy or biologic therapy for the study cancer; note that prior
             chemotherapy or biologic therapy for a different cancer is allowable

          -  Prior therapy that specifically and directly targets the EGFR pathway

          -  History of another primary invasive malignancy except for:

               -  Malignancy treated with curative intent and with no known active disease >= 3
                  years before the first dose of study drug and of low potential risk for
                  recurrence

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease

               -  Adequately treated low risk prostate cancer without evidence of disease

               -  Adequately treated carcinoma in situ without evidence of disease e.g., cervical
                  cancer in situ, and ductal breast carcinoma in situ (DCIS)

          -  History of infusion reaction or hypersensitivity to cetuximab OR allergic reactions
             attributed to compounds of chemical or biologic composition similar to those of
             cetuximab

          -  Documented uncontrolled intercurrent illness or co-morbidity including, but not
             limited to, ongoing or active bacterial or fungal infection requiring intravenous
             antibiotics, uncontrolled congestive heart failure, cardiomyopathy, uncontrolled
             hypertension, unstable angina pectoris, cardiac arrhythmia, acquired immune deficiency
             syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC)
             definition, or psychiatric illness/social situations that would limit compliance with
             study requirements or compromise the ability of the subject to give written informed
             consent

          -  Female subjects who are pregnant or breastfeeding as well as male or female patients
             of reproductive potential who are not employing an effective method of birth control

          -  Patients with clinically relevant coronary artery disease or history of myocardial
             infarction in the last 12 months or high-risk of uncontrolled arrhythmia or
             uncontrolled cardiac insufficiency

          -  Patients with uncontrolled or poorly-controlled hypertension (> 180 mmHg systolic or >
             130 mmHg diastolic)

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of study treatment or interpretation of patient safety or study results

          -  Involvement in the planning and/or conduct of the study